Evidence for link between newer HCV therapies and liver cancer mixed
AMSTERDAM Debate about whether patients taking direct-acting antiviral (DAA) therapies for hepatitis C viral (HCV) infections are at risk of developing liver cancer after achieving sustained virologic response (SVR) continued unabashed Thursday at the European Association for the Study of the Liver's (EASL) annual International Liver Congress.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST